⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15907977 | 0.70 | — | — | |
| SCHEMBL6889646 | 0.69 | — | — | |
| SCHEMBL19542976 | 0.68 | — | — | |
| SCHEMBL12139950 | 0.65 | — | — | |
| Ammonia Solution, Strong SCHEMBL7247171 | 0.63 | HTR1A (0.32) | — | |
| SCHEMBL20034838 | 0.63 | HTR1A (0.32) | — | |
| SCHEMBL20034983 | 0.61 | HTR1A (0.31) | — | |
| SCHEMBL8744971 | 0.61 | — | — | |
| SCHEMBL19293395 | 0.61 | — | — | |
| SCHEMBL16284415 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899317-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-03-19 | — | — | EP | claimed |
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | claimed |
| WO-2007123900-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-01 | — | — | WO | claimed |
| WO-2023228980-A1 | PRODUCTION METHOD FOR FLUOROPOLYETHER GROUP–CONTAINING COMPOUND | ダイキン工業株式会社 | 2023-11-30 | — | — | WO | disclosed |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220087995-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-24 | — | — | US | disclosed |
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10722504-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-10441579-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| EP-2358675-B9 | 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20090318720-A1 | Process for selectively synthesising 3 alpha-hydroxychlormadinone acetate | GRUNENTHAL GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2114862-A1 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE | Merck Generics (UK) Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008093142-A1 | PROCESS FOR THE PREPARATION OF O-DESMETHYL VENLAFAXINE | GENERICS [UK] LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| EP-1899317-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | Teva Pharmaceutical Industries Ltd (IL) | 2008-03-19 | — | — | EP | disclosed |
| US-20080015362-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICALS USA, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007123900-A2 | ENANTIOMERS OF N,N-DIMETHYL-3-(2-THIENYL)-3-HYDROXYPROPANAMINE BORANE AS INTERMEDIATES IN THE SYNTHESIS OF DULOXETINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-01 | — | — | WO | disclosed |
| US-20060241298-A1 | Methods for synthesis of dicarbamate compounds and intermediates in the formation thereof | MEDPOINTE HEALTHCARE INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1582250-A2 | Absorbent with improved ocidation resistance and process for deacidifying fluid fluxes | BASF AKTIENGESELLSCHAFT (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20050202967-A1 | an aliphatic amine, in particular an alkanolamine, and a non-hydroquinoid antioxidant for removal of CO2, H2S, SO2, CS2, HCN, COS, disulfides or mercaptans as impurities in reaction gases formed in the oxidation of organic materials to prevent the emission of above gases | BASF AKTIENGESELLSCHAFT (DE) | 2005-09-15 | — | — | US | disclosed |